2023-07-12 20:12:38
From the General Medicine Unit, Sanofi develops therapies and medicines for the treatment of non-communicable diseases such as diabetes, hypertension, dyslipidemia, thrombosis, cardiovascular diseases, among other conditions of the cardiometabolic system.
As the new general manager of this segment, for the COPAC region (Colombia, Peru, Ecuador, Central America and the Caribbean) that brings together 26 countries of the Americas, Adrien Chabrier assumes the challenge of leading the generation of initiatives that, through the innovation and the power of technology as main allies, contribute to the transformation of the practice of medicine, promoting integrated, more sustainable health systems focused on the well-being of patients.
(Also read: “We have not shown progress in the Invima procedures”: Pharmaceutical Laboratories)
Related topics
“We will continue to combine services, devices and data management that not only improve the practice of health professionals, but also positively impact the experience of people with chronic conditions. My commitment will continue to be promoting care, prevention, raising awareness of the disease, ensuring that there is a synergy between technology and innovation in our processes, seeking the development of high-quality solutions for the benefit of the community”, he highlighted. manager.
Chabrier has been with the French biopharmaceutical company for six years, where he has played various roles to contribute to the pursuit of the power of science to improve people’s lives, including leading the global transformation of General Medicine, the unit that now represents in COPAC.
Precisely, cardiometabolic diseases, which include those of the heart and blood vessels, as well as diabetes, have been a priority for Sanofi, which for more than 50 years has developed a variety of treatments and therapeutic procedures, both for high-risk cardiovascular conditions risk and that require additional medications to those currently available, as well as for the different needs of hyperglycemic patients.
(Read also: Sanofi COPAC leads the synergy between innovation and research)
“We will focus on continuing to strengthen the legacy that we have built for the prevention and treatment of chronic diseases, inspiring the development of more medicines and therapeutic solutions that respond, in an innovative way, to the most urgent medical and social needs of millions of patients with this type of pathologies, also contributing to the sustainability of health systems in the region”, concluded Chabrier.
Chabrier, more than 20 years of experience in the pharmaceutical sector
Adrien Chabrier has had an important career at Sanofi. He first held the position of general manager of the Consumer Healthcare unit in countries such as Portugal, Spain and the Iberian Zone between 2017 and 2021; then, last year, he led the global transformation of the General Medicine unit, to now manage the operation of this business for the COPAC region, which brings together countries such as Colombia, Peru, Ecuador, Central America & the Caribbean.
(Also read: Pharmaceutical Sanofi announces positive results of anticovid vaccine)
Previously, the executive worked for the firm Boehringer Ingelheim for almost 14 years, where he started in the areas of sales, marketing and Business Intelligence in France, to later be the general manager of the Consumer Healthcare business in various countries and the Multi Countries Organization. in Europe, such as Belgium, the Netherlands, Portugal and Spain.
HEALTH UNIT
1689197043
#Frenchman #Adrien #Chabrier #lead #Sanofis #General #Medicine #unit